Atlas Trials

A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy

Clinical trial NCT03404791 · COMPLETED

Trial details

NCT number
NCT03404791
Sponsor
Janssen Research & Development, LLC
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Urinary Bladder Neoplasms
Start date
2017-11-20
Primary completion
2019-12-23
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.